Rulicent 5 mg (Tablet)
Unit Price: ৳ 200.00 (2 x 7: ৳ 2,800.00)
Strip Price: ৳ 1,400.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ruxolitinib oral |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of intermediate or high-risk myelofibrosis in adults
- Treatment of primary myelofibrosis in adults
- Treatment of post-polycythemia vera myelofibrosis in adults
- Treatment of post-essential thrombocythemia myelofibrosis in adults
- Treatment of polycythemia vera in adults
- Treatment of steroid-refractory acute graft-versus host disease in adult and pediatric patients 12 years and older
Pharmacology
- Inhibition of Janus Associated Kinases (JAKs) JAK1 and JAK2
- Modulation of gene expression
- Prevention of splenomegaly
- Decrease of JAK2V617F mutant cells in the spleen
- Decrease of circulating inflammatory cytokines
Dosage
- Recommended starting dose based on platelet count
- Monitoring of complete blood count (CBC)
- Titration of doses based on safety and efficacy
Administration
- Oral administration
- Can be taken with or without food
- Do not take an additional dose if a dose is missed
Interaction
- Concomitant administration with fluconazole greater than 200 mg daily
- Concomitant administration with strong CYP3A4 inhibitors
- Concomitant administration with strong CYP3A4 inducers
Contraindications
- History of hypersensitivity to Ruxolitinib
Side Effects
- Thrombocytopenia
- Anemia
- Neutropenia
- Risk of Infection
- Bruising
- Dizziness
- Headache
- Symptom Exacerbation Following Interruption or Discontinuation of treatment
- Non-Melanoma Skin Cancer
Pregnancy & Lactation
- No adequate and well-controlled studies in pregnant women
- Discontinuation of breastfeeding during treatment with Ruxolitinib
Precautions & Warnings
- Management of thrombocytopenia, anemia, and neutropenia
- Observation for signs and symptoms of infection
- Observation for signs and symptoms of active tuberculosis
- Evaluation for tuberculosis risk factors
- Testing for latent infection in patients at higher risk
- Evaluation for signs and symptoms of progressive multifocal leukoencephalopathy (PML)
- Early recognition and treatment of herpes zoster
- Treatment and monitoring of patients with chronic HBV infection
- Tapering the dose gradually if discontinuing or interrupting therapy
- Performing periodic skin examinations
- Assessment of lipid parameters
- Monitoring of lipid parameters and treatment according to clinical guidelines
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
Overdose Effects
- No known antidote
- Increase in myelosuppression with higher than recommended repeat doses
- Supportive treatment for overdoses
- Hemodialysis not expected to enhance the elimination
Therapeutic Class
- Pyrrolopyrimidines
Storage Conditions
- Store below 30°C
- Dry place, away from sunlight
- Keep out of reach of children